查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2016907

結核病治療藥物市場：依給藥途徑、治療方法、結核病類型及通路分類－2026-2032年全球市場預測

Tuberculosis Drugs Market by Route Of Administration, Treatment Regimen, Tuberculosis Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，結核病治療市場價值將達到 24 億美元，到 2026 年將成長至 25.1 億美元，到 2032 年將達到 33.3 億美元，複合年成長率為 4.77%。

主要市場統計數據
基準年 2025 24億美元
預計年份：2026年 25.1億美元
預測年份 2032 33.3億美元
複合年成長率 (%) 4.77%

簡潔且具有策略意義的介紹，概述了結核病治療的趨勢以及影響經營團隊決策的臨床、監管和商業性環境。

本執行摘要整合了當前影響製藥業應對結核病趨勢的各項議題，並闡述了高階主管必須應對的策略挑戰。內容涵蓋臨床進展、監管政策變化、供應鏈現狀、支付方和醫療服務提供方趨勢以及競爭格局，為董事會層面的討論和商業規劃提供簡明扼要的參考。本文件旨在幫助相關人員清楚了解動態領域、風險集中領域以及臨床實務中治療模式的演變。

近期臨床突破、診斷整合和採購現代化如何從根本上重塑結核病藥物的治療路徑和商業策略。

結核病治療領域正經歷一場變革，其驅動力包括臨床創新、治療指南的修訂以及技術驅動的診斷。全口服療法的引進和短期治療方案的建立，正開始改變許多高發生率地區的處方習慣，而新藥的出現也改變了多重抗藥性結核病的臨床路徑。同時，對以病人為中心的照護和治療服務分散化的日益重視，正促使保險公司和醫療系統優先考慮那些能夠減少住院次數和提高病人用藥依從性的治療方法。

評估 2025 年美國關稅措施將如何重塑結核病治療藥物整個供應鏈的韌性、籌資策略和採購實踐。

美國在2025年實施的關稅和貿易措施，正在全球藥品供應鏈和採購管道中造成明顯的摩擦，而這些管道正是結核病治療藥物供應的基礎。許多藥品製劑和活性成分都依賴複雜的國際網路進行採購。關稅的徵收及相關的行政要求將增加接收成本，改變供應商的選擇標準，並延長關鍵原料的前置作業時間。這些影響將波及採購週期、庫存政策以及製造商、經銷商和公共衛生採購人員之間的合約談判。

詳細的細分分析揭示了管理途徑、治療方法複雜性、疾病症狀和通路如何相互作用，從而塑造產品和服務策略。

細分市場洞察揭示了不同臨床應用場景和通路的動態差異，為產品定位、服​​務模式和商業化計劃提供了重要參考。依給藥途徑分類，市場可分為注射劑和口服製劑。隨著臨床醫生優先考慮縮短住院時間和提高患者遵守用藥，口服療法持續擴張，而注射劑則在特定臨床情況和同情用藥場景中保持著一定的市場地位。依治療方法，相關人員必須應對個人化治療方案與標準化長期和短期治療方案並存的局面。個人化治療方案需要靈活的供應鏈和與診斷的協調配合，而標準化的長期和短期治療方案則受益於精簡的採購流程和計劃周密的部署。

區域分析解釋了流行病學、醫療保健系統能力、採購方法和製造地如何獨特地影響結核病治療的取得和部署。

區域趨勢凸顯了流行病學、醫療衛生系統能力和採購慣例如何導致結核病治療藥物的部署和商業化呈現不同的局面。在美洲，國家計畫和私人醫療機構與不同的製造地並存，支付方的參與重點在於平衡公共衛生需求與預算限制。公共採購機構與區域生產者之間的夥伴關係也影響藥物取得策略。這種差異在歐洲、中東和非洲地區尤其顯著。高所得歐洲國家的醫療衛生系統致力於引進新治療方法並將其與診斷技術相結合，而中東和非洲的許多國家則面臨基礎設施限制，優先考慮簡便、穩健的治療方法以及能夠在物流壓力下正常運轉的供應鏈。

分析製藥公司、非專利生產商和服務型新參與企業之間的競爭定位和夥伴關係模式，以決定競爭和商業化的成功。

製藥公司、非專利生產商和專業供應商之間的競爭與合作動態持續影響著藥物的取得途徑和治療方案的組成。成熟的抗結核基礎藥物生產商與國家採購機構和醫院處方集保持著至關重要的合作關係，這不僅阻礙了藥物的快速替代，也為差異化產品提供了機遇，從而降低治療總成本並簡化物流。同時，研發新型口服療法和創新藥物的創新公司正積極尋求與診斷試劑生產商、非政府執行機構和契約製造建立戰略合作夥伴關係，以加快藥物納入國家治療指南並確保供應承諾。

為產業領導者提供切實可行的建議，以部署整合診斷、多元化供應鏈、確保連續性並加速採用適當治療方法。

產業、公共衛生計畫和採購負責人應採取一系列切實可行的措施，以應對臨床進展、供應鏈中斷和政策不確定性。首先，應優先考慮診斷和治療的整合，使治療方法的選擇與快速且準確的病例發現相符。投資分子診斷和培訓將提高治療方法的合理性，並降低治療失敗的後續成本。其次，關鍵原料藥（API）和製劑的供應商網路應多元化，並儘可能建立本地生產管道，但需滿足一定的條件，以降低貿易政策中斷和對單一來源依賴的風險。

透過結合相關人員訪談、文獻整合、供應鏈映射和情境分析，我們透過高度透明和可重複的調查方法得出可操作的見解。

本研究採用系統性的調查方法，整合一手和二手資料，旨在產生可操作的洞見，同時保持分析的嚴謹性。此方法結合了製藥公司和分銷管道的臨床醫生、採購負責人和高階主管的相關人員，並輔以截至2024年中期的同行評審臨床文獻、監管指南和專案報告的系統性回顧。研究運用資料三角測量法，協調不同觀點，並辨識不同地區和相關人員類型之間的通用主題。

結論強調，必須整合臨床、供應鏈和商業性方法，才能將治療方面的進步轉化為患者永續的治療機會。

總之，結核病治療正處於轉折點，臨床創新、診斷整合和供應鏈韌性將共同決定哪些治療方法能夠成為常規療法。短期全口服療法和新藥的標靶應用在提高患者依從性和計畫實施方面具有顯著優勢，但其療效取決於可靠的診斷、穩定的供應鏈和切實可行的採購方式。貿易政策趨勢和關稅措施帶來了新的營運風險，企業必須透過供應商多元化和策略在地化來積極應對這些風險。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 結核病治療市場：依給藥途徑分類

  • 注射藥物
  • 口服

第9章：治療方法的結核病藥物市場

  • 個人化治療
  • 長期治療
  • 短期治療

第10章：以結核病類型分類的結核病治療市場

  • 肺外
  • 肺結核

第11章 結核病治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 結核病治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 結核病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 結核病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國結核病治療市場

第16章：中國結核病治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • F. Hoffmann-La Roche Ltd
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson
  • Lupin Limited
  • Otsuka Pharmaceutical Co., Ltd.
  • Oxford Immunotec
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc
Product Code: MRR-03252A5F9277

The Tuberculosis Drugs Market was valued at USD 2.40 billion in 2025 and is projected to grow to USD 2.51 billion in 2026, with a CAGR of 4.77%, reaching USD 3.33 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.40 billion
Estimated Year [2026] USD 2.51 billion
Forecast Year [2032] USD 3.33 billion
CAGR (%) 4.77%

A concise and strategic introduction framing the clinical, regulatory, and commercial contexts shaping tuberculosis drugs and the decisions leaders must make

This executive summary synthesizes contemporary dynamics shaping pharmaceutical responses to tuberculosis and frames the strategic questions that senior leaders must answer. The content aggregates clinical advances, regulatory shifts, supply chain realities, payer and provider behaviors, and competitive positioning to create a concise reference that supports board-level discussions and commercial planning. It is written for stakeholders who require clarity on where momentum exists, where risk concentrations lie, and how treatment paradigms are evolving in clinical practice.

The opening context highlights the sustained global public health imperative posed by tuberculosis alongside significant therapeutic innovation. Over recent years, clinicians and national programs have increasingly emphasized shorter, all-oral regimens for many forms of drug-resistant disease, while diagnostics improvements are enabling earlier detection and more precise treatment selection. These clinical shifts intersect with supply chain dependencies, pricing pressures, and regulatory adaptations, creating both opportunities and imperatives for manufacturers, distributors, and clinical networks.

This introduction positions the subsequent sections to examine transformative shifts, tariff-related impacts, segmentation- and region-specific implications, competitor intelligence, actionable recommendations, and the methodology underpinning the research. The aim is to equip decision-makers with an integrated perspective that balances clinical realities with commercial execution.

How recent clinical breakthroughs, diagnostic integration, and procurement modernization are fundamentally reshaping treatment pathways and commercial strategies for tuberculosis therapeutics

The landscape for tuberculosis therapeutics is undergoing transformative shifts driven by clinical innovation, revised treatment guidelines, and technology-enabled diagnostics. Adoption of all-oral regimens and the consolidation of shorter-course options have begun to change prescribing habits in many high-burden settings, while the emergence of novel agents has altered clinical pathways for multidrug-resistant disease. At the same time, increased emphasis on patient-centered care and decentralization of treatment delivery is prompting payers and health systems to prioritize regimens that reduce hospitalization and improve adherence.

These therapeutic advances are accompanied by changes in regulatory frameworks and procurement practices that favor accelerated pathways for drugs addressing unmet needs. Manufacturers and clinical program managers must navigate an environment where real-world evidence and programmatic data carry rising weight in reimbursement discussions and national treatment policy updates. Additionally, investment in point-of-care and molecular diagnostics is improving case detection and enabling more targeted therapy selection, creating stronger linkages between diagnostic capacity and demand for specific drug regimens.

Collectively, these shifts are reshaping competitive dynamics, forcing suppliers to differentiate through formulary access, service offerings such as cold chain and distribution support, and partnerships that connect clinical trial outcomes to implementation at scale. The result is a more integrated ecosystem in which therapeutic value is determined not only by efficacy but also by delivery model, adherence support, and alignment with national TB control priorities.

Assessment of how 2025 tariff measures in the United States are reshaping supply chain resilience, sourcing strategies, and procurement behavior across tuberculosis drug supply networks

The introduction of tariffs and trade measures in the United States during 2025 is creating measurable friction across global pharmaceutical supply chains and procurement channels that support tuberculosis drug availability. Many finished pharmaceuticals and active pharmaceutical ingredients are sourced through complex international networks; the imposition of duties and related administrative requirements increases landed costs, alters supplier selection calculus, and extends lead times for critical inputs. These effects ripple through procurement cycles, inventory policies, and contractual negotiations between manufacturers, distributors, and public health purchasers.

In response, manufacturers and national programs are reassessing sourcing strategies and accelerating supplier diversification, including nearshoring and qualifying alternative API suppliers to mitigate single-source exposure. Payers and large institutional purchasers are revisiting contractual terms and inventory buffers to preserve continuity of supply while managing price pressures. Regulatory agencies and customs authorities are also evolving procedural guidance to expedite essential medicines, but uncertainty in tariff policy can still incentivize stockpiling or conservative procurement that distorts normal purchasing patterns.

For commercial stakeholders, the tariff environment increases the strategic importance of operational agility and cost-to-serve optimization. Firms that can reconfigure supply chains, localize critical manufacturing steps, and demonstrate resilient distribution channels will reduce exposure to trade-policy volatility. Meanwhile, public health programs will need to weigh short-term cost implications against the longer-term imperatives of treatment continuity and programmatic outcomes, balancing fiscal stewardship with patient-centered service delivery.

Deep segmentation analysis revealing how route of administration, regimen complexity, disease presentation, and distribution channels interact to shape product and service strategies

Segmentation insight reveals differentiated dynamics across clinical use cases and distribution pathways, with implication for product positioning, service models, and commercialization plans. Based on route of administration, the landscape is divided between injectable and oral therapies, where oral regimens continue to expand as clinicians favor reduced hospitalization and improved patient adherence, while injectable options retain niche roles for specific clinical circumstances and compassionate-use scenarios. Based on treatment regimen, stakeholders must navigate the coexistence of individualized regimen approaches alongside long-course and short-course standardized regimens; individualized regimens require flexible supply and diagnostic linkage, whereas standardized long-course and short-course options benefit from streamlined procurement and programmatic rollout.

Based on tuberculosis type, the clinical and logistical requirements differ substantially between extrapulmonary and pulmonary presentations, with extrapulmonary disease often necessitating longer diagnostic workups and multidisciplinary care, and pulmonary disease remaining the major driver of transmission-control strategies. Based on distribution channel, hospital pharmacy, online pharmacy, and retail pharmacy pathways each present distinct commercialization considerations: hospital pharmacy channels demand integration with inpatient formularies and clinical stewardship programs, online pharmacy channels require robust cold chain and regulatory compliance for cross-border delivery, and retail pharmacy channels depend on community-level prescribing patterns and patient access programs.

These segmentation axes interact: for example, the adoption of short-course oral regimens for pulmonary TB may shift demand toward retail and online distribution for outpatient management, while individualized regimens for extrapulmonary or drug-resistant cases will concentrate demand in hospital pharmacy and specialty distribution channels. Effective commercial strategies will therefore align product portfolios and service propositions with route-of-administration preferences, regimen complexity, disease presentation, and channel-specific operational requirements.

Regional intelligence describing how epidemiology, health system capacity, procurement modalities, and manufacturing footprints uniquely shape tuberculosis drug access and implementation

Regional dynamics underscore how epidemiology, health system capacity, and procurement practices create distinct contexts for deployment and commercialization of tuberculosis therapeutics. In the Americas, national programs and private-sector providers coexist with diversified manufacturing footprints, and payer engagement focuses on balancing public health imperatives with budgetary constraints; partnerships between public procurement agencies and regional manufacturers influence access strategies. In Europe, Middle East & Africa, heterogeneity is significant: high-income European systems concentrate on novel treatment adoption and integration with diagnostics, while many countries within the Middle East & Africa region face infrastructural constraints that prioritize simple, resilient regimens and supply chains able to operate under logistical stress.

In the Asia-Pacific region, where a substantial burden of tuberculosis persists in several countries, the interplay of local manufacturing capabilities, large-scale public procurement programs, and evolving treatment guidelines drives rapid implementation of newer regimens in some settings while others continue incremental transitions. Regional procurement mechanisms, donor-funded programs, and public-private partnerships remain important levers to accelerate access, but local regulatory harmonization and capacity building for diagnostics are often prerequisites for widescale adoption.

Across all regions, tailored strategies that account for national policy environments, distribution network maturity, and clinician practice patterns will be essential. Commercial and public health actors should calibrate engagement models to regional priorities, investing in diagnostic linkage, training, and supply-chain strengthening where needed to translate therapeutic potential into measurable patient benefit.

Analysis of competitive positioning and partnership models among manufacturers, generic producers, and service-oriented entrants that determine access pathways and commercialization success

Competitive and partnership dynamics among pharmaceutical firms, generic manufacturers, and specialty suppliers continue to shape access pathways and therapeutic mix. Established producers of foundational anti-tuberculosis agents maintain critical relationships with national procurement agencies and hospital formularies, which creates barriers to rapid displacement but also opportunities for differentiated offerings that reduce total cost of care or simplify logistics. At the same time, innovators bringing newer oral regimens and novel agents are pursuing strategic alliances with diagnostic companies, non-governmental implementers, and contract manufacturers to accelerate inclusion in national treatment guidelines and secure supply commitments.

Generic manufacturers play a central role in expanding geographic access, particularly through licensed production and voluntary licensing frameworks that enable broader distribution in low- and middle-income countries. Specialty suppliers and contract manufacturing organizations are increasingly important partners for scaling production of newer compounds and ensuring compliance with international quality standards. Meanwhile, service-oriented entrants that package therapeutics with adherence support tools, digital monitoring platforms, and supply-chain visibility solutions are creating competitive differentiation beyond the core molecule.

For incumbent and new entrants alike, winning in this environment requires a dual focus on clinical evidence generation and implementation science. Firms that can demonstrate real-world effectiveness, safety across diverse populations, and cost-and-care pathway advantages will gain traction with payers and national programs. Strategic licensing, targeted R&D investments, and flexible commercial models that accommodate both programmatic procurement and private-sector channels will be decisive features of successful company strategies.

Actionable recommendations for industry leaders to align diagnostics, diversify supply chains, and deploy integrated service models that secure continuity and accelerate appropriate regimen adoption

Leaders across industry, public health programs, and procurement agencies should adopt a set of practical actions to navigate clinical evolution, supply chain turbulence, and policy uncertainty. First, prioritize integration between diagnostics and therapeutics to ensure regimen selection aligns with rapid and accurate case detection; investments in molecular diagnostics and training will improve regimen appropriateness and reduce downstream costs associated with treatment failure. Second, diversify supplier networks for critical APIs and finished dosage forms while building conditional local manufacturing options where feasible to reduce exposure to trade-policy disruptions and single-source dependencies.

Third, design commercial offerings that combine product access with implementation support, leveraging digital adherence tools, patient education, and tailored service bundles to enhance uptake and real-world outcomes. Fourth, engage proactively with regulatory authorities and national programs to provide robust real-world evidence and post-marketing safety data that can accelerate guideline inclusion. Finally, adapt contracting and pricing approaches to accommodate public-sector procurement cycles and donor-funded programs, while preserving commercial viability through tiered access models and outcome-linked agreements.

Taken together, these steps constitute a pragmatic roadmap to sustain supply continuity, accelerate appropriate regimen adoption, and align commercial execution with public health objectives. Organizations that operationalize these recommendations will be better positioned to deliver clinical value and maintain resilient operations amid evolving policy and clinical landscapes.

Transparent and reproducible research methodology combining stakeholder interviews, literature synthesis, supply-chain mapping, and scenario analysis to generate actionable intelligence

This research synthesizes primary and secondary intelligence through a structured methodology designed to produce actionable insights while preserving analytical rigor. The approach combined targeted stakeholder interviews with clinicians, procurement officials, and senior executives across manufacturers and distribution channels, supplemented by a systematic review of peer-reviewed clinical literature, regulatory guidance, and programmatic reports up to mid-2024. Data triangulation was applied to reconcile differing perspectives and identify persistent themes across geographies and stakeholder types.

Qualitative findings were contextualized by supply-chain mapping exercises and scenario analysis to assess operational sensitivities to trade-policy changes and sourcing disruptions. Case studies illustrating successful regimen adoption and implementation were selected to highlight transferable lessons and operational enablers. The research also incorporated a review of clinical guideline updates and regulatory approvals that materially affect treatment pathways, ensuring alignment between clinical evidence and commercial implications.

Throughout, ethical standards for interview consent and data confidentiality were maintained, and limitations are transparently acknowledged where public data are incomplete or where evolving clinical evidence could alter strategic implications. The methodology emphasizes reproducibility and practical relevance, enabling stakeholders to adapt the analytical framework to their internal decision processes.

Concluding synthesis emphasizing the imperative for integrated clinical, supply-chain, and commercial approaches to translate therapeutic advances into sustained patient access

In conclusion, the tuberculosis therapeutics landscape is at an inflection point where clinical innovation, diagnostics integration, and supply-chain resilience collectively determine which therapies will achieve routine use. Shorter, all-oral regimens and targeted use of novel agents offer substantive benefits for patient adherence and programmatic delivery, but their impact depends on reliable diagnostics, secure supply chains, and pragmatic procurement approaches. Trade-policy developments and tariff measures introduce a new layer of operational risk that organizations must actively mitigate through supplier diversification and strategic localization.

Companies that pair clinical credibility with implementation capabilities-such as adherence support, diagnostic linkage, and flexible distribution models-will be best positioned to translate therapeutic advancements into sustained patient access. Public health programs and donors should continue to prioritize investments that strengthen the diagnostic-to-treatment continuum and support procurement mechanisms that preserve continuity of care. The path forward requires collaborative approaches that align commercial incentives with public health objectives to ensure that advances in therapy translate into better outcomes for patients living with tuberculosis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Tuberculosis Drugs Market, by Route Of Administration

  • 8.1. Injectable
  • 8.2. Oral

9. Tuberculosis Drugs Market, by Treatment Regimen

  • 9.1. Individualized Regimen
  • 9.2. Long Course
  • 9.3. Short Course

10. Tuberculosis Drugs Market, by Tuberculosis Type

  • 10.1. Extrapulmonary
  • 10.2. Pulmonary

11. Tuberculosis Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Tuberculosis Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Tuberculosis Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Tuberculosis Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Tuberculosis Drugs Market

16. China Tuberculosis Drugs Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Cipla Limited
  • 17.6. Dr. Reddy's Laboratories Limited
  • 17.7. F. Hoffmann-La Roche Ltd
  • 17.8. Glenmark Pharmaceuticals Limited
  • 17.9. Johnson & Johnson
  • 17.10. Lupin Limited
  • 17.11. Otsuka Pharmaceutical Co., Ltd.
  • 17.12. Oxford Immunotec
  • 17.13. Sun Pharmaceutical Industries Limited
  • 17.14. Teva Pharmaceutical Industries Limited
  • 17.15. Viatris Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TUBERCULOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TUBERCULOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INDIVIDUALIZED REGIMEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INDIVIDUALIZED REGIMEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INDIVIDUALIZED REGIMEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LONG COURSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LONG COURSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LONG COURSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SHORT COURSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SHORT COURSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SHORT COURSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY EXTRAPULMONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY EXTRAPULMONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY EXTRAPULMONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PULMONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PULMONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PULMONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 38. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 39. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 42. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 44. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 49. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 51. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 64. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 65. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 70. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 80. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 81. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 85. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 86. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 96. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 101. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 106. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 112. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. CHINA TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 117. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)